Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumasiran in infants and young children with PH1
NCT03905694Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6. Started Apr 2019; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT03905694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905694.